0.2276 -0.004 (-1.64%) | 07-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 0.35 ![]() |
1-year : | 0.42 |
Resists | First : | 0.3 ![]() |
Second : | 0.36 |
Pivot price | 0.24 ![]() |
|||
Supports | First : | 0.21 ![]() |
Second : | 0.18 ![]() |
MAs | MA(5) : | 0.23 ![]() |
MA(20) : | 0.25 ![]() |
MA(100) : | 0.29 ![]() |
MA(250) : | 0.47 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 26.6 ![]() |
D(3) : | 27.1 ![]() |
RSI | RSI(14): 37.5 ![]() |
|||
52-week | High : | 12 | Low : | 0.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AZTR ] has closed above bottom band by 8.0%. Bollinger Bands are 23.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.24 - 0.24 | 0.24 - 0.24 |
Low: | 0.22 - 0.22 | 0.22 - 0.22 |
Close: | 0.22 - 0.23 | 0.23 - 0.23 |
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Thu, 03 Jul 2025
Azitra Inc Approves Increase in Common Stock Shares - TipRanks
Wed, 18 Jun 2025
Azitra Inc Plans Stock Increase at Annual Meeting - TipRanks
Tue, 17 Jun 2025
Azitra Inc Announces Positive Phase 1b Trial Results - TipRanks
Tue, 17 Jun 2025
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome - PR Newswire
Tue, 13 May 2025
Azitra Advances Novel Skin Disease Treatments: Key Trial Results Expected in 2025 - Stock Titan
Thu, 24 Apr 2025
$20M Strategic Investment Accelerates Azitra's Breakthrough Treatments for 150,000 Rare Disease Patients - Stock Titan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
AMEX
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 8 (M) |
Held by Insiders | 6.83e+006 (%) |
Held by Institutions | 10.6 (%) |
Shares Short | 311 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.012e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -35 % |
Return on Assets (ttm) | 470.3 % |
Return on Equity (ttm) | -93.5 % |
Qtrly Rev. Growth | 408200 % |
Gross Profit (p.s.) | 0.02 |
Sales Per Share | 0.05 |
EBITDA (p.s.) | -0.63 |
Qtrly Earnings Growth | 92.3 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -9 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 4.39 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 208380 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |